Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma by Lu, L et al.
Title Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma
Author(s) Tian, J; Ma, J; Ma, K; Ma, B; Tang, X; Baidoo, SE; Tong, J; Yan,J; Lu, L; Xu, H; Wang, S
Citation PLoS One, 2012, v. 7 n. 10, p. e46936
Issued Date 2012
URL http://hdl.handle.net/10722/186440
Rights Creative Commons: Attribution 3.0 Hong Kong License
Up-Regulation of GITRL on Dendritic Cells by WGP
Improves Anti-Tumor Immunity in Murine Lewis Lung
Carcinoma
Jie Tian1, Jie Ma1, Ke Ma1, Bin Ma1, Xinyi Tang1, Samuel Essien Baidoo1, Jia Tong1, Jun Yan2, Liwei Lu3,
Huaxi Xu1, Shengjun Wang1*
1Department of Laboratory Medicine, The Affiliated People’s Hospital, Jiangsu University School of Medical Science and Laboratory Medicine, Zhenjiang, China, 2 Tumor
Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, Kentucky, United States of America, 3Department of Pathology and Centre of
Infection and Immunology, The University of Hong Kong, Hong Kong, China
Abstract
Background: b-Glucans have been shown to function as a potent immunomodulator to stimulate innate and adaptive
immune responses, which contributes to their anti-tumor property. However, their mechanisms of action are still elusive.
Glucocorticoid-induced TNF receptor ligand (GITRL), a member of the TNF superfamily, binds to its receptor, GITR, on both
effector and regulatory T cells, generates a positive co-stimulatory signal implicated in a wide range of T cell functions,
which is important for the development of immune responses.
Methodology/Principal Findings: In this study, we found that whole b-glucan particles (WGPs) could activate dendritic cells
(DCs) via dectin-1 receptor, and increase the expression of GITRL on DCs in vitro and in vivo. Furthermore, we demonstrated
that the increased GITRL on DCs could impair the regulartory T cell (Treg)-mediated suppression and enhance effector T cell
proliferation in a GITR/GITRL dependent way. In tumor models, DCs with high levels of GITRL were of great potential to
prime cytotoxic T lymphocyte (CTL) responses and down-regulate the suppressive activity of Treg cells, thereby leading to
the delayed tumor progression.
Conclusions/Significance: These findings suggest that particulate b-glucans can be used as an immunomodulator to
stimulate potent T cell-mediated adaptive immunity while down-regulate suppressive immune activity via GITR/GITRL
interaction, leading to a more efficient defense mechanism against tumor development.
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Introduction
b-Glucans are well-known biological response modifiers (BRMs)
that have been used to treat cancer for many years with varying
and unpredictable efficacy. b-Glucans are extracted from the cell
wall of fungi, yeast or bacteria, consisting of b-1,3-linked D-
glucopyranosyl residues with b-1,6-linked D-glucopyranosyl side
chains of varying length and distribution frequency [1]. Over the
past decades, b-glucans have been recognized as pathogen-
associated molecular patterns (PAMPs) by innate immune system.
Thus far, there are four b-glucan receptors that have been
identified: complement receptor 3 (CR3, CD11b/CD18, Mac-1,
aMb2 integrin) [2], dectin-1 [3,4,5], lactosylceramide (LacCer) [6]
and scavenger receptor (SR) [7]. However, dectin-1 is the main
receptor mediating the activity on macrophages and dendritic cells
(DCs) [8,9]. Engagement of dectin-1 by b-glucan can trigger a
series of intracellular signal transduction pathways through Syk
kinase and Raf-1signaling pathway, activating the cells and
inducing a variety of cellular responses, such as cytokine
production [10,11,12]. Recent findings have demonstrated that
b-glucans are capable of functioning as a potent adjuvant to
stimulate innate and adaptive immune responses [3,13,14,15].
Glucocorticoid-induced TNFR family-related receptor (GITR)
and its ligand, GITRL, are members of the TNFR/ligand
superfamilies [16]. GITR is at low levels on conventional T cells
and is up-regulated upon activation of CD4+ T cells and CD8+ T
cells, but it is particularly expressed at high levels on CD4+CD25+
regulatory T cells (Tregs). The high level of GITR expression by
Treg cells indicates its essential role for this subset
[17,18,19,20,21]. GITRL is expressed on the surface of various
antigen-presenting cells (APCs), including DCs, macrophages and
B cells [22,23]. GITR/GITRL interplay is considered in a wide
range of immune functions involving both effector and Treg cells
[21,24]. Indeed, GITR engagement on effector T cells by
agonistic Abs or recombinant GITRL in vitro exhibits positive
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co-stimulatory signals for TCR-stimulated T cell activation,
leading to increased T cell proliferation and cytokine production
[17,18,22,25,26]. Additionally, triggering of GITR on Treg cells
in co-culture with effector T cells has been suggested to abrogate
the suppressive capacity of Treg cells [19,27]. However, some
other studies indicate that GITR ligation on Treg cells does not
affect the suppressive activity of Tregs themselves, but the
engagement of GITR on effector T cells allows them to escape
suppression by regulatory T cells [22]. In conclusion, the GITR/
GITRL interaction proves to be an effective approach to
manipulate the activity of both effector T cells and Treg cells,
which is suggested to be an essential therapeutic target.
In this study, we demonstrated that whole b-glucan particles
(WGPs) could activate and maturate DCs, and up-regulate the
GITRL expression on DCs both in vitro and in vivo, thus promoting
the proliferation of CD4+CD252 effector T cells, leading to
augmented cytotoxic T lymphocyte (CTL) responses via GITR/
GITRL interaction in tumor models. Furthermore, we showed
that the engagement of GITR/GITRL could also impair Treg
cell-mediated suppression in vitro and abrogate peripheral Treg
suppressive capacity in tumor-bearing mice. More importantly,
the tumor infiltrated Treg cells were reduced, suggesting a
localized abrogation of suppression. All these effects promote
anti-tumor immunity and provide a more efficient defense
mechanism against tumor development.
Results
WGP induces the up-regulation of GITRL on BMDCs via
dectin-1
First, we investigated the expression of dectin-1 on BMDCs.
Flow cytometry analysis showed that BMDCs expressed dectin-1
(Figure 1A). The geometric mean fluorescence intensity (Geo MFI)
of dectin-1 on BMDCs was 6.0160.99, while isotype was
3.3160.18. In order to investigate whether the downstream
signaling molecule SYK could be activated in BMDCs after WGP
stimulation, SYK was assayed at different time points upon WGP
treatment. As indicated in Figure 1B, WGP stimulation induced
SYK activation, and a significant up-regulation of SYK phos-
phorylation in BMDCs was at about 15–20 min post stimulation
(P-SYK/b-actin IOD: 0.007860.0018 vs 0.065460.0075,
P,0.001). Next, we determined the expression of GITRL on
BMDCs after WGP stimulation and found that the GITRL level
was dramatically increased at 48 h (red line, Geo MFI: 26.60)
upon WGP treatment (Figure 1C). To further investigate whether
the increase of GITRL was mediated by dectin-1, anti-dectin-1
antibody was used for blocking. Addition of anti-dectin-1 antibody
in the presence of WGP-stimulated BMDCs partially reversed the
effect that WGP induced while the control IgG did not. As
indicated in Fig. 1D, after the dectin-1 was inhibited, GITRL
expression was down-regulated. In addition, we studied the
expression of other co-stimulatory molecules, including CD40,
CD80, CD86 and MHCII in WGP-stimulated BMDCs and found
Figure 1. Up-regulation of GITRL on BMDCs via dectin-1 upon WGP stimulation. (A) Expression of dectin-1 on BMDCs. BMDCs were stained
for dectin-1 with anti-dectin-1 antibody (thick line) or rat IgG2b (solid gray) and then analyzed using flow cytometry. (B) Analysis of the activation of
SYK by immunoblot of lysates of BMDCs stimulated with WGP (time, above lanes), assessed with anti-phospho-SYK antibody (upper band). b-actin
levels were measured as protein loading controls (lower band). (C) Flow cytometry for surface expression of GITRL on BMDCs after no stimulation or
stimulation with WGP for 24 h, 48 h and 72 h. (D) BMDCs were pretreated with anti-dectin-1 mAb or rat IgG (5 mg/ml) for 1 h at 37uC and then
treated with 100 mg/ml WGP, after 48 h stimulation, cells were subjected to analyze the GITRL expression. The values shown in the flow cytometry
profiles are geometric mean fluorescent intensity. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0046936.g001
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that the expression of CD40, CD80, CD86 and MHCII was
significantly increased (data not shown). Taken together, WGP
could induce the activation and maturation of DC through dectin-
1, and up-regulate GITRL expression on them in vitro.
WGP-induced enhancement of GITRL impairs Treg cell-
mediated suppression and enhances the effector T cell
proliferation
It has been suggested that GITR/GITRL interaction functions
as a co-stimulating signal and modulates T cell activation and
function [28]. Having observed the up-regulated expression of
GITRL on BMDCs by WGP, we next investigated whether the
increased GITRL would alter the activation or function of T cells
via GITR/GITRL interplay. First, we co-cultured CD4+CD25+
Treg cells and CD4+CD252 Teff cells with WGP-treated
BMDCs or non-treated BMDCs. As shown in Figure 2A,
significant reduction of percentage of inhibition was observed in
the presence of WGP-treated BMDCs when compared with non-
treated cells. To further investigate whether the reduction of
inhibition was caused by the up-regulation of GITRL on BMDCs
and GITR/GITRL interaction in part mediated this response,
anti-GITRL antibody was used for blocking. Addition of anti-
GITRL antibody in the presence of WGP-stimulated BMDCs
partially reversed the inhibition extent while the control Ig did not.
This suggests that the Treg cell-mediated suppression might be
inhibited by GITR/GITRL interplay. Next, we co-cultured Teff
cells with WGP-stimulated BMDCs or non-treated cells and found
that the proliferation of Teff cells was efficiently enhanced in the
presence of WGP-treated BMDCs. However, the enhanced
proliferation response was inhibited by the addition of anti-
GITRL antibody (Figure 2B). Therefore, the enhancement of
GITRL on BMDCs can regulate the suppressive effect induced by
Treg cells and enhance the proliferation of Teff cells which are
GITR/GITRL pathway dependent.
WGP treatment in vivo significantly enhances GITRL
expression on DCs and delays tumor progression
Having observed that WGP could increase the GITRL
expression on BMDC in vitro, we next investigated whether
WGP treatment would regulate the GITRL in vivo and have any
effect on tumor therapy. To this end, C57BL/6 mice orally
administered with or without WGP for 7 days were implanted with
LLC tumor cells. Mice were continuously treated with or without
WGP for another 3 weeks. As shown in Figure 3A, tumor-bearing
mice treated with WGP exhibited a significantly slower tumor
progression as compared to those treated with PBS. To further
evaluate whether the delayed tumor development was caused by
the increased GITRL by WGP treatment, we used GITR to block
the GITR/GITRL interaction in vivo. It was obvious that tumor
grew faster after GITR treatment while the control protein did
not. It suggests that WGP could delay the tumor progression by
up-regulating GITRL in vivo.
We next examined the expression of GITRL on DCs in tumor-
bearing mice. Cells from spleens, draining lymph nodes and
tumors in tumor-bearing mice treated with or without WGP were
subjected to analyze the GITRL expression on DCs by flow
cytometry. As shown in Figure 3B and 3C, the proportions of DCs
in draining lymph nodes and tumors, and GITRL expression on
DCs were significantly increased upon WGP treatment. In
addition, GITRL mRNA levels in draining lymph nodes and
tumors were dramatically up-regulated in WGP-treated group. All
these data indicate that WGP treatment is able to increase the
GITRL expression on DCs in vivo and subsequently slow tumor
development.
Augmented CTL responses are induced by up-regulation
of GITRL following WGP treatment
We further determined the potential of enhanced GITRL on
DCs to prime CD8+ T cells. Lymphocytes from spleens, draining
lymph nodes and tumors in tumor-bearing mice treated with or
without WGP were analyzed. Increased proportions of
CD3+CD8+ T cells in spleens and draining lymph nodes were
observed after WGP treatment (data not shown). As depicted in
Figure 4, augmented CD8+IFN-c+ CTLs in spleens (Figure 4A)
and draining lymph nodes (Figure 4B) were induced in response to
Figure 2. Increased GITRL expression on BMDCs by WGP
impairs Treg-mediated suppressive effect and enhances Teff
proliferation. Murine CD4+CD252 Teff and CD4+CD25+ Treg cells were
purified from C57BL/6 mice splenocytes as described in Materials and
Methods. BMDCs were stimulated with WGP (100 mg/ml) or not for 24 h.
Cells were harvested, treated with mitomycin C and then co-cultured at
a 1:5 ratio with CD4+CD252 Teff and CD4+CD25+ Treg cells (A) or Teff
cells (B) in the presence of anti-CD3 mAb with or without anti-GITRL
blocking antibody or control Igs for 72 h, Treg and Teff cells were
added at 1:1 ratio. Wells were pulsed with 1 mCi/well [3H]-thymidine for
the last 16 h. Data are expressed as means6 SD. ***P,0.001, **P,0.01,
*P,0.05. N.S. represents no significance between columns.
doi:10.1371/journal.pone.0046936.g002
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WGP treatment. Moreover, production of IFN-c in culture
supernatants from splenocytes and lymphoid cells was increased
in WGP-treated group as compared to PBS control. Further, in
local tumor sites, proportions of CD3+CD8+ T cells and IFN-c
mRNA levels were enhanced in WGP-treated mice (Figure 4C).
However, the augmented CTL responses were reversed after the
blocking treatment with GITR, which further suggests that WGP
could boost the CTL responses in a GITR/GITRL dependent
way.
Increased GITRL induced by WGP inhibits the suppressive
function of regulatory T cells in tumor-bearing mice
Our in vitro experiment has indicated that the increased GITRL
induced by WGP could inhibit the suppressive effect of Treg cells.
Next, we determined whether the enhanced GITRL would have
any effect on the activation and function of Treg cells in tumor
models. As shown in Figure 5C, the percentages of
CD4+CD25+Foxp3+ Treg cells infiltrated in tumor sites were
dramatically decreased after WGP treatment, and were again
reversed to high levels after GITR blocking treatment. In contrast,
the proportions of Treg cells in spleens and draining lymph nodes
were not altered after WGP treatment (Figure 5A and 5B).
Strikingly, the suppressive activity of splenic Treg cells was
substantially down-regulated after WGP treatment in vivo
(Figure 5D). All these data suggest that, GITR/GITRL interaction
could abrogate suppressive cells in local sites. In addition, although
the engagement of GITR on splenic Treg cells failed to affect the
proportions of peripheral Treg cells, it modulated the suppressive
capacity of Treg cells.
Discussion
b-Glucans have shown great success in cancer treatment as
immunotherapeutic agents for centuries. b-Glucans are reported
to have significant therapeutic efficacy in murine breast, liver
metastasis, lung, and lymphoma tumor models as well as in human
lymphoma and neuroblastoma when used in combination with
anti-tumor mAbs [29,30,31,32,33]. Previous studies have demon-
strated that b-glucans play an essential role in innate immune
responses, and the mechanism in cancer therapy was mainly via
stimulation of macrophages and priming of neutrophil comple-
ment receptor 3 for eliciting CR3-dependent cellular cytotoxicity
of iC3b-opsonized tumor cells [34,35,36]. However, recent studies
have suggested that b-glucans also have a critical role in regulating
adaptive immune responses. It is reported that bacterial b-glucan
curdlan-stimulated DCs could prime Th1, CTL and Th17 cells
and convert Treg into IL-17-producing T cell via dectin-1
dependent pathway [37,38]. In addition, recent studies reveal
that yeast zymosan b-glucan appears to induce regulatory APCs
leading to Treg differentiation [39,40]. Moreover, a new report
indicates that the particulate yeast-derived b-glucans WGPs can
stimulate DC activation and maturation both in vitro and in vivo,
leading to augmented Ag-specific CD4 and CD8 T cell responses,
which bridges innate and adaptive immunity [15]. All these new
emerging data suggest b-glucans could drive all arms of adaptive
immune responses as potential immunomodulatory agents. In this
study, we found that yeast-derived particulate b-glucans could
activate DCs through dectin-1 to up-regulate the co-stimulatory
molecule GITRL in vitro. Moreover, WGP in vivo treatment
significantly increased the proportions of DC in tumor-bearing
mice, especially in local tumor sites, and up-regulated GITRL
expression on DCs, thus promoting the maturation of DCs,
enhancing their capacity to activate adaptive T cell responses and
eliciting anti-tumor immunity.
Since GITR was discovered in 1997, it has been the focus of
many studies that investigate its biological function in cellular
immunology [16,17]. GITR is constitutively expressed on non-
activated T cells and is especially abundant on CD4+CD25+ Treg
cells. GITR activation, upon interaction with its ligand GITRL,
functions as a co-activating signal [21]. Collectively, GITR
triggering has two distinct effects. One is activating effector T cells,
promoting their proliferation and making them more resistant to the
Treg cell-mediated suppression. The other is abrogating the
suppressive function of Treg cells or deletion of Treg cells. As our
in vitro proliferation assays showed, the increased GITRL by WGP
stimulation could impair the suppressive effect of Treg cell mediated
and enhance the proliferation of effector T cells. This notion was
further supported by adding agonistic anti-GITRL antibody to co-
cultures of suppressor and responder T cells which led to a reversal
of suppressive activity. Actually, upon the activation of DCs, apart
from the GITRL enhancement, some other co-stimulatory mole-
cules were also up-regulated, including CD40, CD80, CD86 and
MHCII (data not shown). As shown in Figure 2, inhibition of
GITR/GITRL interaction couldn’t completely reverse the effect.
Nevertheless, the role of GITR/GITRL played in the co-culture
system was relatively dominant. In Lewis lung carcinoma model,
orally administered WGP treatment significantly enhanced the
GITRL on DCs in vivo. Therefore, those activated DCs with
increased GITRL modulated anti-tumor responses from two sides,
one was eliciting enhanced CTL responses, the other was down-
regulation the suppressive capacity of Treg cells, which were both
GITR/GITRL dependent. Mechanisms for immune suppression
include both failure of immune T cell infiltrating into tumors and
the presence of suppressive cells at tumor sites, such as regulatory T
cells. Therefore, the most challenge task in tumor immunotherapy is
to reverse the suppressive tumor microenvironment. In our study,
we showed that particulate b-glucan WGPs modulated the tumor
microenvironment towards anti-tumor responses via actively
recruiting plenty of DCs with high GITRL expression into the
tumor milieu, thus, eliciting augmented anti-tumor CD8 T cell
responses and reducing the Treg cells infiltrated in tumors. Taken
together, WGPs alter the suppressive environment and promote the
effective adaptive immune responses via GITR/GITRL interac-
tion, therefore, leading to an efficient approach to treat cancers.
One of the most efficient approaches in cancer immunotherapy
is elicitation of potent anti-tumor T cell responses while down-
regulation of immunosuppressive factors in patients with cancer.
Actually, adjuvants have been widely used in cancer immuno-
therapy to potentiate anti-tumor T cell responses and modulate
the activity of suppressive cells. Moreover, GITR/GITRL
Figure 3. WGP treatment up-regulates GITRL expression on DCs in tumor-bearing C57BL/6 mice. (A) Groups of mice (n = 6) bearing
established Lewis lung carcinoma were treated as described in Materials and Methods. Tumors were measured with a caliper at indicated time. (B) The
proportions of CD11c+ DCs in spleens, draining lymph nodes (dLN) and tumor tissues from WGP-treated or untreated mice were analyzed using flow
cytometry. (C) Expression of GITRL on CD11c+ cells in spleens, draining lymph nodes and tumor sites treated with or without WGP were assessed by
flow cytometry. Histograms are gated on CD11c+ cells (isotype: solid gray). RNAs extracted from spleens, draining lymph nodes and tumors were
subjected to qRT-PCR for GITRL expression. Numbers indicate percentages of events in gate (dot plot) or geometric mean fluorescence intensity
(GeoMFI; histograms). Results are expressed as mean 6 SD. ***P,0.001, **P,0.01, *P,0.05, ###P,0.001, N.S. represents no significance between
columns.
doi:10.1371/journal.pone.0046936.g003
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interaction has been proved to be an effective way to manipulate
the T cell activity. In our study, we demonstrate that WGP could
activate DCs via dectin-1 and up-regulate the GITRL expression
on DCs, thus the GITR/GITRL interaction acts as a co-activating
signal to augment efficient anti-tumor T cell responses and
drastically alter the suppressive effect of regulatory T cells, leading
to delayed tumor development. We thus provide novel insights
into the mechanism of WGP in modulating adaptive immune
responses and its function in anti-tumor immunity. Our findings
highlight the benefit of particulate b-glucan treatment in cancer
patients as an adjuvant and its potential for clinical application by
promoting the effect of cancer immunotherapy.
Materials and Methods
Particulate yeast-derived b-glucan WGP
WGP (Eagan) was highly purified from the cell wall of
Saccharomyces cerevisiae and was composed mainly of b-1,3/1,6-
glucan. The particulate b-glucan WGP contains .85% b-glucan,
,3.5% protein, ,0.01% manan, and ,8% moisture. To remove
any traces of LPS contamination, the WGP was suspended in
200 mM NaOH for 20 minutes at room temperature (RT), then
washed thoroughly, and finally re-suspended in LPS-free water
[41]. The endotoxin level was 0.06 EU/mL as tested by the gel-
clot method (Associates of Cape Cod).
Bone marrow-derived DC (BMDC)
BM cells were isolated by flushing femurs and tibiae with
complete RPMI 1640 medium using a 1 ml syringe. The complete
RMPI 1640 medium was prepared by adding 10% heat-
inactivated newborn calf serum (NCS) (GIBCO), 50 mM 2-
mercaptoethanol and penicillin/streptomycin to RPMI 1640
medium (GIBCO). BM cells were seeded into 6-well plates
(Corning) at 2.56106/ml in complete RPMI 1640 medium
supplemented with 10 ng/ml granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Clongene Biotech) and 10 ng/ml
IL-4 (PeproTech). Cells were cultured under 37uC, 5% CO2 in a
humidified atmosphere. On day 2, medium was replaced with
fresh medium supplemented with GM-CSF. On day 5, half of the
medium was removed and fresh GM-CSF-supplemented medium
was added into cultures. On day 7, the non- and loosely adherent
cells were harvested and used for experiments.
Western blot analysis
Proteins extracted from cells were prepared as described
previously [42]. Proteins were separated by sodium-dodecyl-
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred onto immobilon PVDF membranes (Bio-Rad), and probed
with rabbit phospho-SYK antibody (Cell Signaling Technology)
and mouse b-actin antibody (Abcam) followed by chemilumines-
cent detection (Champion Chemical).
In vitro proliferation assays
In our in vitro experiments, CD4+CD25+ Treg cells and
CD4+CD252 T cells were isolated from wild-type C57BL/6 mice
splenocytes with a CD4+ T cell negative selection kit (Invitrogen),
FITC-conjugated anti-CD25 mAb (BD Pharmingen) and anti-
FITC microbeads (Miltenyi Biotec). The purity of isolated
CD4+CD25+ Treg cells and CD4+CD252 T cells was .90%
(data not shown). BMDCs were pretreated with or without WGP
for 24 h, and then the cells were harvested and treated with
mitomycin C (Kyowa, 50 mg/ml) for 20 min. For co-stimulation
assays, 56104 CD4+CD252 T cells were co-cultured with 16104
mitomycin C-treated BMDCs in the presence of 10 mg/ml anti-
CD3 mAb in triplicate in round-bottom 96 wells. For Treg assays,
CD4+CD25+ Treg cells were added to the same conditions as
described above at a Treg:Teff ratio of 1:1. Where indicated,
100 mg/ml anti-GITRL antibodies were added into the wells for
blocking. In tumor models, CD4+CD25+ Treg cells from the
spleens of WGP-treated or untreated tumor-bearing C57BL/6
mice were co-cultured with CD4+CD252 T cells from wild-type
C57BL/6 mice spleens, CD4+CD252 T cells were plated at
56104 as responder cells with CD4+CD25+ suppressor cells at the
following ratios of suppressor cells: responder cells 1:1, 1:5, 1:10.
Cells were incubated in the presence of anti-CD3 (10 mg/ml) and
anti-CD28 (Biolegend, 5 mg/ml) mAbs. In all settings, cells were
incubated for 72 h and pulsed with [3H]-thymidine (Pharmacia,
1 mCi/well) for the last 16 h of culture. Data from the co-culture
were expressed as the % inhibition = [12(cpm(CD4+CD252 plus
CD4+CD25+)/cpm CD4+CD252)]6100 or stimulation index
(SI) = cpm in stimulated culture/cpm in unstimulated culture
[43]. % inhibition represented the inhibition of suppression and
the uninhibited proliferation of Teff cells was used as 100%.
Cell line, mice and tumor models
The Lewis lung carcinoma (LLC) cells were obtained from
American Type Culture Collection. Specific pathogen free male
C57BL/6 mice were purchased from Yangzhou University. All
experiments were approved by the Institutional Committee on the
Use of Animals for Research and Teaching,Jiangsu University.
For tumor models, C57BL/6 mice were treated with 200 ml of
yeast-derived particulate b-glucan WGP (4 mg/ml in PBS; total
800 mg) or 200 ml PBS given every other day with an intragastric
gavage needle for 7 days. Then, mice were implanted subcuta-
neously (s.c.) with LLC cells (36106/mouse). After tumor
challenge, therapy was continuously administered for 3 weeks.
Where indicated, GITR (500 mg/mouse) or control protein was
administered intraperitoneally (i.p.) every other day to tumor-
bearing mice on 2 day after the implantation of LLC cells. Tumor
growth was monitored with bidirectional tumor measurements
using calipers every 2 days and tumor volume was calculated using
the formula V = 0.5ab2 with ‘‘a’’ as the larger diameter and ‘‘b’’ as
the smaller diameter.
Preparation of single cell suspension from tumors
Tumors were weighed and minced into small (1–2 mm3) pieces
and immersed in 10 ml of digestion mixture including 5% NCS in
RPMI 1640, 0.5 mg/ml collagenase A (Sigma-Aldrich), 0.2 mg/
ml hyaluronidase (Sigma-Aldrich), and 0.02 mg/ml DNase I
(Sigma-Aldrich) per 0.25 g of tumor tissues. This mixture was
incubated at 37uC for 1.5 h on a rotating platform. Then the cell
suspensions were filtered through 70 mm cell strainers (BD Falcon)
Figure 4. WGP induces enhanced CTL priming in vivo. Groups of mice (n = 6) bearing established Lewis lung carcinoma were treated as
described in Materials and Methods. (A, B) Single cell suspensions prepared from spleens (A) and draining lymph nodes (B) were stimulated with PMA
plus ionomycin and stained intracellular IFN-c. Cells were gated on CD3+CD8+ T cells. Culture supernatants from splenocytes and lymphoid cells were
collected and assayed for IFN-c using ELISA. (C) Tumor specimens from each group were prepared for single cell suspensions. Cells were stained with
mAbs against CD3, CD8 and were assessed by flow cytometry. Cells were gated on CD3+ T cells. RNAs from tumor specimens were extracted and qRT-
PCR was performed for IFN-c. Results are expressed as mean 6 SD. **P,0.01, *P,0.05, N.S. represents no significance between columns.
doi:10.1371/journal.pone.0046936.g004
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and washed twice with ice cold PBS. Remaining red blood cells
were lysed in ammonium chloride solution.
Tumor infiltrated lymphocytes (TILs) isolation
TILs were isolated from tumor suspensions by density gradient
centrifugation using Percoll (GE health). Briefly, cells were
suspended in 80% Percoll, overlayed with 40% Percoll, and
centrifuged at 20006g for 30 minutes. Cells at the interface were
collected [44].
Flow cytometry
Spleens and draining lymph nodes were grinded with the 5 ml
plunger of syringe, then the cell suspensions were filtered through
70 mm cell strainers (BD Falcon) and washed with ice cold PBS.
Remaining red blood cells were lysed in ammonium chloride
solution. Cells were harvested, Fc receptors were blocked by
incubation in HB197 supernatant, stained with relevant antibodies
in PBS for 30 min at 4uC. For surface markers, single cell
suspensions were stained with FITC-conjugated CD11c and PE-
conjugated GITRL mAbs (eBioscience). Anti-dectin-1 (Invivogen)
and FITC-conjugated goat anti-rat IgG (KPL) were used to detect
the dectin-1 expression. For intracellular cytokine staining, single
cell suspensions were stimulated with PMA (Sigma-Aldrich,
50 ng/ml), ionomycin (Enzo, 1 mg/ml), monensin (Enzo, 2 mg/
ml). After 5 h, cells were stained with anti-CD3 and anti-CD8
mAbs (eBioscience), fixed, permeabilized and stained with anti-
IFN-c mAb (eBioscience) according to the Intracellular Staining
Kit (Invitrogen) instructions. For Treg cell staining, anti-CD4,
anti-CD25 and anti-Foxp3 mAbs (eBioscience) were performed
following Foxp3 Staining Buffer Set (eBioscience) protocols. Flow
cytometry was performed using FACSCalibur Flow Cytometer
(Becton Dickinson) and data were analyzed using WinMDI 2.8
software.
Quantitative real-time PCR (qRT- PCR)
Total RNA was prepared with TRIzol (Invitrogen). To remove
the possible contamination of genomic DNA, we treated the total
RNA with DNase I (TaKaRa) before reverse transcription. cDNA
was synthesized with ReverTra Ace qPCR RT kit (TOYOBO)
according to the manufacturer’s instructions. The indicated
mRNA levels were quantified by qRT-PCR amplification using
the Rotor-Gene 6000 (Corbett Research). Briefly, the cDNA was
amplified in a 25 ml reaction mixture containing 12.5 ml SYBR
Green Mix (TaKaRa), 200 nM of each primer, 100 ng of cDNA
using the recommended cycling conditions. primer sequences were
as follows: b-actin, 59-TGGAATCCTGTGGCATCCATGAA-
AC-39 (forward), 59-TAAAACGCAGCTCAGTAACAGTCCG-
39 (reverse); GITRL, 59- CTACGGCCAAGTGATTCCTGT -39
(forward), 59-GATGATCCCCCAGTATGTGTT -39 (reverse);
IFN-c, 59-CGCTACACACTGCATCTTGG -39 (forward), 59-
TGAGCTCATTGAATGCTTGG -39 (reverse); Foxp3, 59-CCA-
CTGGGGTCTTCTCCCTCAA -39 (forward), 59-CATTTGCC-
AGCAGTGGGTAGGA -39(reverse). Relative quantification of
mRNA expression was calculated by the comparative threshold
cycle (Ct) method [45].
Enzyme-linked immunosorbent assay (ELISA)
IFN-c content in the supernatants from splenocyte and
lymphoid cell cultures were measured by sandwich ELISA
(eBioscience).
Statistical analysis
The statistical significance of differences between groups was
determined by the Student’s t test or two-way analysis of variance.
All analyses were performed using SPSS11.5 software. Differences
were considered significant at a P level less than 0.05.
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